LEVONORGESTREL AND ETHINYL ESTRADIOL TAB

The contract specifies the procurement of Levonorgestrel and Ethinyl Estradiol Tablets, USP, a hormonal contraceptive formulation regulated by the FDA, with a standardized dosage cycle consisting of six sequential phases totaling 28 tablets per cycle and 168 tablets per unit of issue, equivalent to six full cycles. Each cycle includes six tablets with 50 mcg levonorgestrel and 30 mcg ethinyl estradiol, followed by five tablets with 75 mcg levonorgestrel and 40 mcg ethinyl estradiol, ten tablets with 125 mcg levonorgestrel and 30 mcg ethinyl estradiol, and seven inert placebo tablets. The product must have a minimum of 21 months of remaining shelf life at the time of receipt by the first government activity, with a total shelf life of 24 months, and must be stored at controlled room temperature between 20°C and 25°C. Packaging and marking must strictly conform to Medical Marking Standard No. 1A dated February 4, 2013, replacing all references to MIL-STD-129, and each unit must be sealed in a protective container capable of preventing damage during transit. Shipments must be packed in commercial exterior containers suitable for safe delivery at the lowest carrier rate to the designated destination, with delivery required within 20 days FOB destination under a zero variance acceptance policy. The item is sourced from Teva Pharmaceuticals USA, Inc., with NDC 00555-9047-58, and the procurement falls under NSN 6505-01-224-0176. The contract references the DLA Master List of Technical and Quality Requirements and requires confirmation via EBS referral by the contracting official, including manufacturer and bidder details. The solicitation, issued under SPE2DP-26-T-4123, has a response deadline of July 20, 2026, and is managed by the Department of Defense’s Medical Supply Chain.